Mutations impacting myeloid malignancies can be divided by five classes: spliceosome components (e.g., Splicing factor 3B subunit 1 (SF3B1)), epigenetic regulators (e.g., DNA methyltransferase 3A (DNMT3A),), signalling pathway proteins (fms-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2)), transcription factors (CCAAT enhancer-binding protein alpha (CEBPA), runt-related transcription factor 1 (RUNX1)) and tumour suppressor proteins (Tumour protein p53 (TP53)) [5]. Here, SF3B1 is linked to cancer.